|
| 36690537 | Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates. | Cytotherapy | 2023 |
| 37749187 | Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. | Bone Marrow Transplant | 2023 |
| 37236188 | Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques. | Immunity | 2023 |
| 36441905 | Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. | Blood Adv | 2023 |
| 34741653 | Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise? | Support Care Cancer | 2022 |
| 36446398 | Iatrogenic systemic lymphedema following multiple myeloma treatment. | Lymphology | 2022 |
| 34971577 | Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. | Lancet Haematol | 2022 |
| 34815518 | Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. | Bone Marrow Transplant | 2022 |
| 33901720 | Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse. | Transplant Cell Ther | 2021 |
| 32324888 | A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. | Blood Adv | 2020 |
| 31930750 | Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications. | Xenotransplantation | 2020 |
| 31056994 | Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy. | Leuk Lymphoma | 2019 |
| 31124175 | Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. | Am J Hematol | 2019 |
| 30836091 | Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged â¿¥70 years. | Hematol Oncol Stem Cell Ther | 2019 |
| 31085121 | Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors. | Cytotherapy | 2019 |
| 29459665 | A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). | Bone Marrow Transplant | 2018 |
| 29127275 | Allogeneic stem cell transplantation in fully MHC-matched Mauritian cynomolgus macaques recapitulates diverse human clinical outcomes. | Nat Commun | 2017 |
| 25555450 | Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial. | Biol Blood Marrow Transplant | 2015 |
| 25961774 | Chronic GvHD-associated serositis and pericarditis. | Bone Marrow Transplant | 2015 |
| 25759146 | Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. | Biol Blood Marrow Transplant | 2015 |
| 25445641 | Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population. | Biol Blood Marrow Transplant | 2015 |
| 24650974 | Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. | Clin Lymphoma Myeloma Leuk | 2014 |
| 22909078 | Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. | Intern Med J | 2013 |
| 19781656 | Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. | Biol Blood Marrow Transplant | 2010 |
| 20603622 | Is it time for a change? The case for early application of unrelated allo-SCT for severe aplastic anemia. | Bone Marrow Transplant | 2010 |
| 19171207 | The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. | Semin Hematol | 2009 |
| 19327589 | Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention. | Hematol Oncol Clin North Am | 2009 |
| 19327576 | Bone marrow failure syndromes. Preface. | Hematol Oncol Clin North Am | 2009 |
| 18024607 | Bone marrow failure as a risk factor for clonal evolution: prospects for leukemia prevention. | Hematology Am Soc Hematol Educ Program | 2007 |
| 16940417 | Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). | Blood | 2006 |
| 12627847 | Management issues in paroxysmal nocturnal hemoglobinuria. | Int J Hematol | 2003 |
| 9149777 | Transmission of human immunodeficiency virus through blood transfusion: the use of lookback and traceback approaches to optimize recipient identification in a regional population. | Transfusion | 1997 |
| 7922946 | Use of blood donation history of people with HIV infection to identify recipients at risk. | CMAJ | 1994 |